Drug intelligence / Profile preview

omega-3 fatty acids (SickKids)

Development stage
Phase 1
Lead developer
SickKids
Modality
Small Molecules
Administration
Oral
01

Overview

Omega Pure is an omega-3 fatty acid supplement consisting of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). It was evaluated as an investigational therapy in a Phase 2 clinical trial (NCT00691288) sponsored by The Hospital for Sick Children for the management of hypertriglyceridemia in pediatric patients with HIV who are undergoing highly active antiretroviral therapy (HAART). The mechanism of action involves the reduction of hepatic triglyceride synthesis, likely through the inhibition of enzymes such as diacylglycerol O-acyltransferase and the activation of peroxisome proliferator-activated receptor alpha (PPAR-alpha), which enhances fatty acid oxidation and triglyceride clearance via lipoprotein lipase activation.

Brand names
Omega Pure
Other names
fish oilomega-3 fatty acid supplementationomega3 fatty acid supplementationomega 3 fatty acid supplementation
02

Targets

DGAT2 (Hepatic diacylglycerol acyltransferase 2)LPL (Lipoprotein lipase)PPARA (Peroxisome proliferator-activated receptor alpha)DGAT1 (Diacylglycerol O-acyltransferase 1)

Beyond the preview

Go deeper on omega-3 fatty acids (SickKids).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on omega-3 fatty acids (SickKids).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call